Galapagos NV (NASDAQ:GLPG) Short Interest Update

Galapagos NV (NASDAQ:GLPG - Get Free Report) was the recipient of a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 2,170,000 shares, a growth of 25.4% from the February 13th total of 1,730,000 shares. Based on an average daily volume of 262,700 shares, the short-interest ratio is presently 8.3 days. Currently, 4.5% of the company's stock are sold short.

Galapagos Stock Up 0.6 %

NASDAQ:GLPG traded up $0.15 during trading hours on Wednesday, hitting $25.99. 37,324 shares of the company were exchanged, compared to its average volume of 183,214. Galapagos has a 52-week low of $22.36 and a 52-week high of $34.02. The company's 50 day moving average price is $24.99 and its 200-day moving average price is $27.07.

Wall Street Analysts Forecast Growth

GLPG has been the topic of several research reports. Kepler Capital Markets lowered shares of Galapagos from a "hold" rating to a "reduce" rating in a report on Wednesday, November 20th. Barclays restated an "underweight" rating on shares of Galapagos in a report on Thursday, January 23rd. TD Cowen lowered shares of Galapagos from a "strong-buy" rating to a "strong sell" rating in a research note on Thursday, January 9th. Finally, Morgan Stanley downgraded shares of Galapagos from an "equal weight" rating to an "underweight" rating and lowered their target price for the company from $31.00 to $22.00 in a research note on Friday, February 14th. Five equities research analysts have rated the stock with a sell rating and four have issued a hold rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Reduce" and an average target price of $26.75.

Remove Ads

Institutional Trading of Galapagos

Several large investors have recently added to or reduced their stakes in the company. Finepoint Capital LP lifted its holdings in shares of Galapagos by 2.8% during the third quarter. Finepoint Capital LP now owns 557,762 shares of the biotechnology company's stock worth $16,058,000 after purchasing an additional 15,000 shares during the period. Erste Asset Management GmbH acquired a new stake in Galapagos during the 3rd quarter valued at approximately $410,000. GAMMA Investing LLC boosted its holdings in shares of Galapagos by 77.4% in the 4th quarter. GAMMA Investing LLC now owns 2,233 shares of the biotechnology company's stock valued at $61,000 after acquiring an additional 974 shares during the last quarter. Crossmark Global Holdings Inc. increased its stake in shares of Galapagos by 31.5% in the fourth quarter. Crossmark Global Holdings Inc. now owns 49,163 shares of the biotechnology company's stock worth $1,352,000 after acquiring an additional 11,777 shares during the period. Finally, R Squared Ltd acquired a new stake in shares of Galapagos in the fourth quarter worth $26,000. Hedge funds and other institutional investors own 32.46% of the company's stock.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.